vs

Side-by-side financial comparison of GOLDEN HEAVEN GROUP HOLDINGS LTD. (GDHG) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

GOLDEN HEAVEN GROUP HOLDINGS LTD. is the larger business by last-quarter revenue ($15.3M vs $12.5M, roughly 1.2× Avidity Biosciences, Inc.). GOLDEN HEAVEN GROUP HOLDINGS LTD. runs the higher net margin — -56.2% vs -1398.3%, a 1342.1% gap on every dollar of revenue.

Golden Heaven Group Holdings Ltd. operates large-scale amusement parks, cultural tourism complexes and family-focused leisure venues primarily across mainland China. Its core services include thrill rides, themed entertainment zones, cultural experience activities, plus supporting catering and retail offerings, catering to leisure demands of consumers across all age groups.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

GDHG vs RNA — Head-to-Head

Bigger by revenue
GDHG
GDHG
1.2× larger
GDHG
$15.3M
$12.5M
RNA
Higher net margin
GDHG
GDHG
1342.1% more per $
GDHG
-56.2%
-1398.3%
RNA

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
GDHG
GDHG
RNA
RNA
Revenue
$15.3M
$12.5M
Net Profit
$-8.6M
$-174.4M
Gross Margin
50.2%
Operating Margin
-44.5%
-1513.5%
Net Margin
-56.2%
-1398.3%
Revenue YoY
434.0%
Net Profit YoY
-117.0%
EPS (diluted)
$-10.83
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GDHG
GDHG
RNA
RNA
Q3 25
$15.3M
$12.5M
Q2 25
$3.8M
Q1 25
$13.8M
$1.6M
Q4 24
$3.0M
Q3 24
$2.3M
Q2 24
$2.0M
Q1 24
$13.8M
$3.5M
Q4 23
$2.2M
Net Profit
GDHG
GDHG
RNA
RNA
Q3 25
$-8.6M
$-174.4M
Q2 25
$-157.3M
Q1 25
$-115.8M
Q4 24
$-102.3M
Q3 24
$-80.4M
Q2 24
$-70.8M
Q1 24
$2.5M
$-68.9M
Q4 23
$-60.4M
Gross Margin
GDHG
GDHG
RNA
RNA
Q3 25
50.2%
Q2 25
Q1 25
52.0%
Q4 24
Q3 24
Q2 24
Q1 24
52.0%
Q4 23
Operating Margin
GDHG
GDHG
RNA
RNA
Q3 25
-44.5%
-1513.5%
Q2 25
-4448.7%
Q1 25
-8360.9%
Q4 24
-4069.6%
Q3 24
-4200.9%
Q2 24
-4040.4%
Q1 24
25.5%
-2178.6%
Q4 23
-3043.5%
Net Margin
GDHG
GDHG
RNA
RNA
Q3 25
-56.2%
-1398.3%
Q2 25
-4089.3%
Q1 25
-7360.0%
Q4 24
-3439.5%
Q3 24
-3441.7%
Q2 24
-3461.8%
Q1 24
18.4%
-1943.4%
Q4 23
-2756.2%
EPS (diluted)
GDHG
GDHG
RNA
RNA
Q3 25
$-10.83
$-1.27
Q2 25
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$-0.65
Q1 24
$-0.79
Q4 23
$-0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GDHG
GDHG
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$86.0M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$180.7M
$1.9B
Total Assets
$191.4M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GDHG
GDHG
RNA
RNA
Q3 25
$86.0M
$350.2M
Q2 25
$243.9M
Q1 25
$19.8M
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$129.4K
$471.4M
Q4 23
$185.1M
Stockholders' Equity
GDHG
GDHG
RNA
RNA
Q3 25
$180.7M
$1.9B
Q2 25
$1.2B
Q1 25
$83.7M
$1.3B
Q4 24
$1.4B
Q3 24
$1.5B
Q2 24
$1.2B
Q1 24
$64.3M
$830.9M
Q4 23
$500.8M
Total Assets
GDHG
GDHG
RNA
RNA
Q3 25
$191.4M
$2.1B
Q2 25
$1.4B
Q1 25
$98.6M
$1.5B
Q4 24
$1.6B
Q3 24
$1.6B
Q2 24
$1.3B
Q1 24
$82.9M
$951.5M
Q4 23
$628.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GDHG
GDHG
RNA
RNA
Operating Cash FlowLast quarter
$19.0M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GDHG
GDHG
RNA
RNA
Q3 25
$19.0M
$-156.2M
Q2 25
$-199.7M
Q1 25
$-124.8M
Q4 24
$-99.9M
Q3 24
$-65.6M
Q2 24
$-65.0M
Q1 24
$-911.6K
$-70.4M
Q4 23
$16.5M
Free Cash Flow
GDHG
GDHG
RNA
RNA
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-924.9K
$-71.3M
Q4 23
$15.6M
FCF Margin
GDHG
GDHG
RNA
RNA
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-6.7%
-2012.3%
Q4 23
713.1%
Capex Intensity
GDHG
GDHG
RNA
RNA
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
0.1%
25.8%
Q4 23
39.4%
Cash Conversion
GDHG
GDHG
RNA
RNA
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.36×
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons